Future Perspectives for the Development of Chemotherapy for Advanced Gastric Cancer: Japanese and Global Status

被引:2
作者
Higuchi, Katsuhiko [1 ]
Tanabe, Satoshi [1 ]
Azuma, Mizutomo [1 ]
Sasaki, Tohru [1 ]
Ishido, Kenji [1 ]
Koizumi, Wasaburo [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Gastroenterol, Minami Ku, Sagamihara, Kanagawa 2520380, Japan
关键词
Gastric cancer; Chemotherapy; Molecular target agent; Personalized therapy; PHASE-III TRIAL; ADVANCED ESOPHAGOGASTRIC CANCER; S-1 PLUS CISPLATIN; 1ST-LINE TREATMENT; FLUOROURACIL; DOXORUBICIN; METHOTREXATE; CAPECITABINE; OXALIPLATIN; MITOMYCIN;
D O I
10.1159/000321700
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In Japan, gastric cancer is the second leading cause of cancer-related mortality after lung cancer. Many randomized trials of various chemotherapeutic regimens have been conducted, contributing to improved outcomes in patients with advanced gastric cancer (AGC). The standard regimen for AGC is a combination of S-1 and cisplatin in Japan. Recently, new drug development has focused on molecular target agents, and personalized therapy for AGC has just begun. In patients with human epidermal growth factor receptor 2-positive AGC, trastuzumab in combination with chemotherapy improves survival. Furthermore, abundant information about the heterogeneity and biological backgrounds of AGC patients has been compiled. New strategies for the development of personalized therapy should be studied in the future. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:334 / 342
页数:9
相关论文
共 50 条
  • [41] A Case of Advanced Gastric Cancer with Folfiri as a Preoperative Chemotherapy
    Hieu Van Nguyen
    Hung Van Nguyen
    Long Thanh Nguyen
    Nga Quynh Pham
    Hau Xuan Nguyen
    Hien Xuan Nguyen
    Vuong Thi Nguyen
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019, 2019
  • [42] Treatment options in patients with metastatic gastric cancer:Current status and future perspectives
    Ahmet Bilici
    World Journal of Gastroenterology, 2014, (14) : 3905 - 3915
  • [43] Treatment options in patients with metastatic gastric cancer: Current status and future perspectives
    Bilici, Ahmet
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (14) : 3905 - 3915
  • [44] A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
    Chao, Yee
    Hsieh, Jan-Sing
    Yeh, Hsien-Tang
    Su, Yu-Chieh
    Wu, Cheng-Chung
    Chen, Jen-Shi
    Tai, Cheng-Jeng
    Bai, Li-Yuan
    Yeh, Kun-Huei
    Su, Wu-Chou
    Li, Chung-Pin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 799 - 806
  • [45] Palliative chemotherapy for advanced gastric cancer
    Wöhrer, SS
    Raderer, A
    Hejna, A
    ANNALS OF ONCOLOGY, 2004, 15 (11) : 1585 - 1595
  • [46] Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer
    Kawakami, Hisato
    Okamoto, Isamu
    Hayashi, Hidetoshi
    Taguri, Masataka
    Morita, Satoshi
    Nakagawa, Kazuhiko
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 3003 - 3009
  • [47] Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer
    Jin, Xin
    Liu, Zhaorui
    Yang, Dongxiao
    Yin, Kai
    Chang, Xusheng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] Radiomics in the Diagnosis of Gastric Cancer: Current Status and Future Perspectives
    Wang, Zhiqiang
    Li, Weiran
    Jin, Di
    Fan, Bing
    CURRENT MEDICAL IMAGING, 2024, 20
  • [49] The current status and future perspectives of laparoscopic surgery for gastric cancer
    Kim, Hyung-Ho
    Ahn, Sang-Hoon
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2011, 81 (03): : 151 - 162
  • [50] Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives
    Sato, Yasushi
    Okamoto, Koichi
    Kawaguchi, Tomoyuki
    Nakamura, Fumika
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    BIOMEDICINES, 2022, 10 (07)